Fibrocel Science

FCSC NASDAQ
1.820
+0.020
+1.11%
After Hours: 1.850 +0.03 +1.65% 17:20 08/16 EDT
Open
1.820
Prev Close
1.800
High
1.866
Low
1.760
Volume
92.26K
Avg Vol (3M)
103.40K
52 Week High
3.280
52 Week Low
1.450
% Turnover
0.95%
Market Cap
17.76M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Fibrocel Science FCSC stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
MORE >

Recently

Name
Price
%Change